Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Sarilumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

48 / 100

Czynniki ryzyka

The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...

The notice references procurement documents and an annex, but only the notice text was provided; the full document set...

Submission deadline in 8 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house rebate agreements for the medicinal product substance Sarilumab, ATC L04AC14.
  • Supply contract for pharmaceutical products.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement for Sarilumab (ATC L04AC14) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2024-11-01 to 2026-10-31, with contract entry possible until 2026-09-05. Submission is allowed electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents. No contract value is stated.

Ryzyka

The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...

The notice references procurement documents and an annex, but only the notice text was provided; the full document set...

Submission deadline in 8 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Sarilumab

Single lot for non-exclusive open-house rebate agreements concerning the pharmaceutical substance Sarilumab (ATC L04AC14). The lot is for supplies and is performance-related to Germany, specifically Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2024 - Oct 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 05, 2026

Szczegóły zamówienia

Data publikacji
16 Sep 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
557248-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30